BioWisdom forms partnership with InPharmix
According to the partnering companies, the incorporation of StAT will facilitate the delivery of MEDLINE literature citations to Discovery Portfolio Users.
By on May 8, 2001According to the partnering companies, the incorporation of StAT will facilitate the delivery of MEDLINE literature citations to Discovery Portfolio Users.
Discovery Portfolio is a customizable drug discovery target tracking system designed for use by the drug discovery scientist. The system is designed to provide alerts to changes in public and proprietary information, which relates to the scientists drug target portfolio. In addition, BioWisdom aggregates and aligns complex disciplinary data, information and technology from both the public domain and from their proprietary partners. Users are able to view meta-data so that they can fully understand what is on offer before purchasing or licensing the information.
InPharmix's StAT tool is designed to search the MEDLINE literature database of more than 10 million abstracts using a user-supplied query. The resulting abstracts are then analysed statistically and the most important finding are extracted and highlighted.
"MEDLINE is an incredibly useful resource, but sometimes finding the most relevant references within it can be a daunting task," said Derek Jones, Commercial Director of BioWisdom. "InPharmix's StAT tool helps manage this complexity, and will provide us with the ability to deliver MEDLINE results to Users of Discovery Portfolio relevant to their specific targets of interest."
According to the partnering companies, the StAT tool allows Discovery Portfolio to summarize MEDLINE data for a scientist's individual portfolio, and will include a link back to the original MEDLINE records.
Biomedical researchers are being swamped with data," said James Sluka, Chief Scientist at InPharmix. "Not only are the sequence databases growing at a dizzying rate, but the biomedical literature is as well. This explosion in data, and the increased use of genomic research methods, presents the researcher with large sets of genes that are pertinent to their research. The days of spending months or years studying a single gene are gone. Researchers must now work with lists of genes, many of which are unfamiliar to the researcher. StAT allows the researcher to quickly generate a concise summary of the biomedical literature concerning a gene, protein, disease, drug or other concept. Incorporation of StAT into Discovery Portfolio allows the researcher to automatically track the literature concerning their genes of interest.